Back to Search
WALTER VALENTINE, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1578903308Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
029476(MO)
Research & Publications (20)
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.
PMID 19330561·Swiss Med Wkly·2009
2-rct
Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
PMID 19545216·J Med Econ·2009
8-other
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
PMID 19640359·Int J Clin Pharmacol Ther·2009
4-observational
N,N-diethyldithiocarbamate promotes oxidative stress prior to myelin structural changes and increases myelin copper content.
PMID 19467251·Toxicol Appl Pharmacol·2009
7-preclinical
Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720.
PMID 19296586·J Org Chem·2009
7-preclinical
Nitrogen substituent polarity influences dithiocarbamate-mediated lipid oxidation, nerve copper accumulation, and myelin injury.
PMID 19093748·Chem Res Toxicol·2009
7-preclinical
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.
PMID 19416529·Cost Eff Resour Alloc·2009
8-other
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.
PMID 18443195·Diabetes Care·2008
8-other
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
PMID 18479280·Int J Clin Pract·2008
4-observational
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
PMID 18568451·Adv Ther·2008
8-other
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
PMID 18704282·Adv Ther·2008
8-other
Neurodegeneration in mice resulting from loss of functional selenoprotein P or its receptor apolipoprotein E receptor 2.
PMID 18172410·J Neuropathol Exp Neurol·2008
7-preclinical
Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.
PMID 18925509·Platelets·2008
7-preclinical
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
PMID 18400145·Curr Med Res Opin·2008
4-observational
Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors.
PMID 18316373·J Biol Chem·2008
7-preclinical
A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
PMID 18359872·Nephrol Dial Transplant·2008
4-observational
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
PMID 18387067·Value Health·2008
8-other
Copper accumulation and lipid oxidation precede inflammation and myelin lesions in N,N-diethyldithiocarbamate peripheral myelinopathy.
PMID 18284930·Toxicol Appl Pharmacol·2008
7-preclinical
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
PMID 19450074·J Med Econ·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 929 HIGHWAY D
OSAGE BEACH, MO 65065 - Phone
- (573) 302-8383
Quick Facts
- NPI
- 1578903308
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile